Corey Nathaniel Cunningham

Corey Nathaniel Cunningham

Auto-generated profile, based on publicly available information

Corey Nathaniel Cunningham

Department of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
MRMadhu Sudhan Ravindran
Madhu Sudhan Ravindran
PBParikshit Bagchi
Parikshit Bagchi
CCCorey Nathaniel Cunningham
Corey Nathaniel Cunningham
BTBilly Tsai
Billy Tsai

1 August 2019 in Molecular Cell
Verified
Journal Article
Closed access
CCCorey N. Cunningham
Corey N. Cunningham
JWJeffrey M. Williams
Jeffrey M. Williams
JKJeffrey Knupp
Jeffrey Knupp
Anoop ArunagiriAnoop Arunagiri
Anoop Arunagiri
PAPeter Arvan
Peter Arvan
BTBilly Tsai
Billy Tsai

28 January 2018 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Anoop ArunagiriAnoop Arunagiri
Anoop Arunagiri
LHLeena Haataja
Leena Haataja
CCCorey N. Cunningham
Corey N. Cunningham
NSNeha Shrestha
Neha Shrestha
BTBilly Tsai
Billy Tsai
PAPeter Arvan
Peter Arvan

1 October 2015 in Molecular Biology of the Cell
Verified
Journal Article
Open access
KHKaiyu He
Kaiyu He
CCCorey Nathaniel Cunningham
Corey Nathaniel Cunningham
NMNandini Manickam
Nandini Manickam
MLMing Liu
Ming Liu
PAPeter Arvan
Peter Arvan
BTBilly Tsai
Billy Tsai
In mutant INS gene–induced diabetes of youth (MIDY), characterized by insulin deficiency, MIDY proinsulin mutants misfold and fail to exit the endoplasmic reticulum (ER). Moreover, these mutants bind and block ER exit of wild-type (WT) proinsulin, inhibiting insulin production. The ultimate fate of ER-entrapped MIDY mutants is unclear, but previous studies implicated ER-associated degradation (ERAD), a pathway that retrotranslocates misfolded ER proteins to the cytosol for proteasomal degradation. Here we establish key ERAD machinery components used to triage the Akita proinsulin mutant, including the Hrd1-Sel1L membrane complex, which conducts Akita proinsulin from the ER lumen to the cytosol, and the p97 ATPase, which couples the cytosolic arrival of proinsulin with its proteasomal degradation. Surprisingly, we find that protein disulfide isomerase (PDI), the major protein oxidase of the ER lumen, engages Akita proinsulin in a novel way, reducing proinsulin disulfide bonds and priming the Akita protein for ERAD. Efficient PDI engagement of Akita proinsulin appears linked to the availability of Hrd1, suggesting that retrotranslocation is coordinated on the lumenal side of the ER membrane. We believe that, in principle, this form of diabetes could be alleviated by enhancing the targeting of MIDY mutants for ERAD to restore WT insulin production.


27 December 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
CCCorey N. Cunningham
Corey N. Cunningham
KHKaiyu He
Kaiyu He
Anoop ArunagiriAnoop Arunagiri
Anoop Arunagiri
APAdrienne W. Paton
Adrienne W. Paton
JPJames C. Paton
James C. Paton
BTBilly Tsai
Billy Tsai
In heterozygous patients with a diabetic syndrome called mutant INS gene–induced diabetes of youth (MIDY), there is decreased insulin secretion when mutant proinsulin expression prevents wild-type (WT) proinsulin from exiting the endoplasmic reticulum (ER), which is essential for insulin production. Our previous results revealed that mutant Akita proinsulin is triaged by ER-associated degradation (ERAD). We now find that the ER chaperone Grp170 participates in the degradation process by shifting Akita proinsulin from high–molecular weight (MW) complexes toward smaller oligomeric species that are competent to undergo ERAD. Strikingly, overexpressing Grp170 also liberates WT proinsulin, which is no longer trapped in these high-MW complexes, enhancing ERAD of Akita proinsulin and restoring WT insulin secretion. Our data reveal that Grp170 participates in preparing mutant proinsulin for degradation while enabling WT proinsulin escape from the ER. In principle, selective destruction of mutant proinsulin offers a rational approach to rectify the insulin secretion problem in MIDY.